

University of Groningen

Immunometabolism in type 2 diabetes mellitus

Pinheiro-Machado, Erika; Gurgul-Convey, Ewa; Marzec, Michal

Published in:
Archive of Medical Science

DOI:
[10.5114/aoms.2020.92674](https://doi.org/10.5114/aoms.2020.92674)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Pinheiro-Machado, E., Gurgul-Convey, E., & Marzec, M. (2023). Immunometabolism in type 2 diabetes mellitus: tissue-specific interactions. *Archive of Medical Science*, 19, 895-911.
<https://doi.org/10.5114/aoms.2020.92674>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Immunometabolism in type 2 diabetes mellitus: tissue-specific interactions

Erika Pinheiro-Machado¹, Ewa Gurgul-Convey², Michal T. Marzec³

¹Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands

²Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany

³Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

Submitted: 14 August 2019; **Accepted:** 23 October 2019

Online publication: 31 January 2020

Arch Med Sci 2023; 19 (4): 895–911

DOI: <https://doi.org/10.5114/aoms.2020.92674>

Copyright © 2020 Termedia & Banach

Corresponding author:

Assoc. Prof. Michal T. Marzec

University of Copenhagen

Department of Biomedical Sciences

Panum Institute, room 12.6.10

Blegdamsvej 3

DK-2200 Copenhagen N

Denmark

E-mail: Michal@sund.ku.dk

Abstract

The immune system is frequently described in the context of its protective function against infections and its role in the development of autoimmunity. For more than a decade, the interactions between the immune system and metabolic processes have been reported, in effect creating a new research field, termed immunometabolism. Accumulating evidence supports the hypothesis that the development of metabolic diseases may be linked to inflammation, and reflects, in some cases, the activation of immune responses. As such, immunometabolism is defined by 1) inflammation as a driver of disease development and/or 2) metabolic processes stimulating cellular differentiation of the immune components. In this review, the main factors capable of altering the immuno-metabolic communication leading to the development and establishment of obesity and diabetes are comprehensively presented. Tissue-specific immune responses suggested to impair metabolic processes are described, with an emphasis on the adipose tissue, gut, muscle, liver, and pancreas.

Key words: immunity, metabolism, tissue-specific, diabetes.

Introduction

Obesity prevalence has doubled in more than 70 countries and continuously increases globally since 1980 [1]. Studies have associated high body mass index (BMI) and physical inactivity with a set of chronic diseases such as type 2 diabetes (T2DM), and an array of other disorders [2–4]. The main link between these metabolic disorders is the ability to induce insulin resistance and, as a consequence, affect the whole organism's function. However, some organs and tissues exacerbate the pathological conditions including: 1) adipose tissue (AT) – the site of fat accumulation, 2) the gut – the site for the microbiota and metabolites that have been associated with metabolic disorders [5], 3) muscles – the primary site of insulin resistance [6], 4) the liver – obesity is a major risk factor for liver damage, and finally, 5) the pancreas – once impaired it leads to compromised insulin production and secretion. All metabolic processes that these organs are involved in are also influenced by immunological responses that stimulate and maintain them.

The interface between the immune system and metabolism has been investigated over the last 15 years and has been branded with the term

immunometabolism. This interdisciplinary approach made the field essential for understanding the pathology and progression of metabolic diseases as immunometabolism places the low-grade chronic inflammation as the central cause and consequence of metabolic disorders [7]. Inflammation is described as a prompt and a short-term response to deal with injuries and infections, providing repair to injured tissues, and it is composed of a series of signals and pathways that are rapidly resolved upon healing. In contrast, low-grade chronic systemic inflammation or metaflammation is primarily caused by persistent activation of the innate immune system that promotes increased production and secretion of proinflammatory cytokines and other mediators [8, 9]. It is generally believed that persistent over-nutrition, physical inactivity and exposure to certain epigenetic factors contribute to the development of low-grade systemic inflammation associated with metabolic diseases [10–12]. The constant activation of the innate immune system has been shown to induce the production of stimuli that may additionally activate the adaptive immune system. In some tissues, such as visceral AT, an alternative chain of events combining the immune response and inflammation was described, in which the adaptive immune cells (CD4 and/or CD8 T cells) were shown to trigger AT inflammation [13, 14]. Together, it is proposed that an interplay between disturbed metabolic state and these low-grade chronic inflammatory responses culminate in a vicious cycle leading to the development of metabolic diseases, such as T2DM [15–17].

An inflammatory state playing a role in the development of metabolic diseases was shown for the first time in 1993 [18] when the adipose tissue (AT) was described to produce the proinflammatory cytokine tumor necrosis factor α (TNF- α). In accordance, it was proposed that obesity could be associated with enhanced expression of proinflammatory mediators and that this environment could modulate glucose metabolism and/or insulin action [19].

Increased serum free fatty acids (FFAs) levels have been associated with insulin resistance in obese individuals [20–23]. Especially saturated FFAs have been correlated with induction of the inflammatory response and insulin resistance in insulin target tissues, while polyunsaturated FFAs have been described as generally anti-inflammatory [24]. In contrast to omega-6 FFAs, omega-3 FFAs by stimulating the biosynthesis of specialized pro-resolving lipid mediators (SPMs; such as protectins, resolvins, lipoxins, maresins) in immune cells and other tissues are believed to possess a strong protective anti-inflammatory potential [25]. Specialized pro-resolving lipid media-

tors were shown to improve insulin sensitivity and reduce AT inflammation via inhibition of TNF- α , IL-1 β , IL-6 and IL-8 secretion [26].

The analysis of AT from obese patients showed that macrophages were able to infiltrate this tissue [27] and that FFAs promoted the polarization of these cells towards a proinflammatory phenotype (M1 macrophages) [28]. It is important to mention that macrophage polarization has been clustered into two major macrophage polarization programs, classically activated macrophages or M1 and alternatively activated macrophages or M2, each related to specific immune responses, among which both progression and resolution of inflammation constitute critical determinants [29]. However, this clear distinction has been challenged with data identifying a metabolically activated macrophage phenotype that is mechanistically distinct from M1 or M2 activation [30, 31].

Nevertheless, the presence of classical M1 macrophages in AT of obese patients and high-fat fed animal models (HFD; HFD-fed M-JAK2^{-/-} and HFD-fed MIF^{-/-} C57BL/6J) was clearly associated with impaired insulin action [32, 33]. Beyond the innate immune system, it has also been demonstrated that the adaptive immune response with T and B lymphocytes may influence metabolic processes. So far, the immuno-metabolic crosstalk has been described in various tissues, suggesting functional links with consequences for translational studies [34, 35].

This review aims to present and discuss the updated knowledge about important processes in the intercommunication between the immune system and metabolism (Figure 1). Although much of what is known about these interactions during obesity and obesity-related diseases was first described in AT, other organs are also involved and they will be discussed in more detail in forthcoming sections.

Tissue-specific immune responses leading to metabolic diseases

Adipose tissue

Initially treated as a deposit for triacylglycerol and thus as a sole energy-storage tissue, the AT is now considered a multifunctional endocrine organ that is able to synthesize bioactive factors (adipokines) to regulate metabolism, energy intake, fat storage and immunity [36, 37]. Composed mainly of adipocytes, the AT also contains pre-adipocytes, endothelial cells, fibroblasts, and a diversity of immune cells such as macrophages, neutrophils, T lymphocytes, and others, with clear differences observed between obese and lean adipose tissue, as well as distinct functions of visceral fat (VAT) and subcutaneous fat (SAT) [38, 39].




Figure 1. Important processes in the intercommunication between the immune system and metabolism

[This figure was created using images from Servier Medical Art Commons Attribution 3.0 Unported License. (<http://smart.servier.com>). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License]

The volume of abdominal visceral fat area was the most predictive factor for AT macrophage infiltration in patients [39], and correlated with increased proinflammatory mediator secretion [40]. In lean individuals only 10% of AT is composed of macrophages and they are predominantly in the anti-inflammatory M2 state [41]. In contrast, in obese individuals up to 50% of AT consists of M1 macrophages [42, 43]. TNF- α released from M1 macrophages can inhibit the transcription factor PPAR γ that is responsible for the ability of AT to produce new healthy fat cells from stem cells [44]. Consequently, the decreased capability for generation of new healthy fat cells together with a parallel overexpansion of inflamed adipocytes results in the acceleration of necrotic cell death of adipocytes. This process triggers the aggravation of AT inflammation through migration of neutrophils and macrophages [45–47].

Alterations in the AT immune status influence cytokine content, adipocyte metabolism and insulin sensitivity. Proinflammatory adipokines stimulate local recruitment and accumulation of inflammatory cells in AT as well as increasing the systemic levels of inflammatory markers [48–50]. This is the mechanism suggested to trigger the low-grade

chronic inflammation that is directly related to the development of various diseases, such as obesity, T2DM, cardiovascular pathologies or cancer [51, 52].

The major immuno-metabolic interaction taking place in the obese AT is the adipocyte-macrophage crosstalk [53]. The inflamed environment is not only a result of the TNF- α production by adipocytes [18] but also a result of macrophage activity. M1 macrophages secrete high levels of chemokines and proinflammatory cytokines, fostering the insulin-resistant state in AT [16, 54]. It has been shown that amelioration of AT inflammation strongly correlates with a decreased number of proinflammatory macrophages as well as reduction of the whole-body insulin resistance [55, 56]. Other proinflammatory factors that impair insulin signaling in the AT include activation of the nuclear factor- κ B (NF- κ B) [57, 58], and c-Jun N-terminal kinase (JNK) [59] pathways in adipocytes, as well as induction of oxidative stress [60]. Once active, these components stimulate the transcription of genes that, 1) encode pro-inflammatory proteins, 2) inhibit the activation of the insulin receptor, and, 3) impair processes such as the PI3K/Akt/mTOR pathway resulting in defective insulin signaling [61].

Interleukin-6 (IL-6), secreted by the adipocytes, stromal cells and macrophages, also affects insulin sensitivity in the AT through similar mechanisms and its serum level positively correlates with the degree of obesity in humans [62–64]. Although its activity impairs insulin signaling [65], the absence of IL-6 leads to the development of obesity and insulin resistance [66, 67], suggesting that a certain threshold of IL-6 concentration is required for unbiased AT function. The appetite-control adipokine leptin is another factor considered as a crucial pro-inflammatory contributor to AT dysfunction [68], capable of activating macrophages [69], and promoting glucose metabolism in CD4⁺ Th1 cells [70–72]. Finally, neutrophils, which are the first immune cells recruited to the AT in obese animals fed a HFD [73], have also been shown to participate in the AT inflammatory response and malfunction. When present in the AT, neutrophils secrete neutrophil elastase, which hampers insulin signaling through degradation of the insulin receptor substrate 1 (IRS-1) [73]. This process was shown to be attenuated in HFD exercise-trained mice [74].

Interestingly, apart from the innate immune cell components, lymphocytes have also been shown to be engaged in the regulation of the inflammation-metabolic state axis of AT. After macrophages, CD3⁺ T cells are the largest population of immune cells present in the AT with even more abundant presence in response to increasing adiposity [75]. Besides CD3⁺, the levels of CD8⁺ and CD4⁺ T cells are also elevated during obesity [76–78], mostly in VAT [79, 80]. The increase in CD8⁺ T cells is suggested to precede and contribute to the accumulation of macrophages in the AT, and their depletion is associated with the decrease of M1 macrophages and insulin resistance improvement [76]. The CD4⁺ (Th1) increase is suggested to have a pathological role in obesity and obesity-induced insulin resistance. It was demonstrated that activated CD4⁺ T cells (CD4⁺CD44^{hi}CD62L^{lo}) accumulate in the visceral AT of obese mice and display features of cellular senescence [81]. In addition, the MHC class 2 induction in the obese AT activates CD4⁺ T cells, which triggers AT inflammation and insulin resistance [82]. $\gamma\delta$ T cells, when in the white adipose tissue (WAT) and after long-term HFD, are present in high numbers and secrete high amounts of IL-17, a cytokine that regulates adipogenesis and glucose metabolism [83]. Animals lacking $\gamma\delta$ T cells display reduced HFD-induced inflammation, while the presence of these cells positively contributes to WAT inflammation by regulating the macrophage populations present in the tissue [84]. It is important to point out that the dynamics of the immune system within VAT and SAT is remarkably different [85, 86].

On the other hand, Th2 cells are suggested to play a protective role against systemic inflammation and insulin resistance by producing type 2 cytokines (IL-4, IL-5, IL-13) and stimulating polarization of macrophages to M2 phenotypes. Production of Th2 cytokines, such as IL-10, was reported to occur in SAT, indicating an anti-inflammatory role of this fat depot [87–89]. CD4⁺ T cells once transferred into a diet-induced obesity animal model were shown to acquire a Th2 profile. The observation was associated with a reduction of body weight and insulin resistance improvement [88, 90]. An unbalanced ratio between Th1 and Th2 cells is strongly associated with systemic inflammation and insulin resistance [88]. T regulatory cells (Tregs), a cell type that generally inhibits the acceleration of inappropriate inflammatory processes, thereby maintaining insulin sensitivity [91], are also involved. Tregs display reduced levels during obesity [92], while non-obese AT is rich in Tregs [14]. It was demonstrated that obese mice with adipocytes lacking MHC class 2 and consequently displaying lower amounts of IFN- γ presented a higher number of Tregs, which led to reduced obesity-induced AT inflammation and insulin resistance [92]. In addition, imbalances between Tregs and Th17 cells, characterized by the production of proinflammatory cytokines such as IL-17A, IL-22, and IL-21 [93], caused by lipotoxicity were shown to contribute to obesity and T2DM progression [94]. Ablation of Tregs specifically in the AT of HFD-fed animals resulted in impaired insulin sensitivity [92].

B lymphocytes have been shown to accumulate before T cells in the AT in HFD models [95] and are recruited by the pro-inflammatory chemokines produced by the AT (CXCL10/CCL2/CCL5) [96], and through leukotriene LTB4 signaling [97]. A pathogenic role for B cells was reported, leading to enhancement of the AT insulin resistance [98]. B cell accumulation is associated with M1 macrophage polarization, activation of T cells (CD4⁺ and CD8⁺), and production of pathogenic IgG antibodies [98]. A distinct B cell subtype, called the B regulatory cell (Breg), was reported as a constitutive subset with an anti-inflammatory profile within AT. Bregs maintain tissue homeostasis, produce IL-10, and their function is impaired during obesity [99]. Bregs were shown to have a central contribution to the progression of obesity-induced inflammation, displaying reduced numbers in the obese AT [99, 100]. The same study showed a causal relationship between increased levels of Th1 cytokines and decreased frequency of Bregs [100]. Another anti-inflammatory agent influencing the AT metabolism is the cytokine IL-37. Transgenic mice expressing IL-37 were found to be protected against metabolic syndrome even when fed a HFD [101].

Moreover, HFD-fed mice treated with recombinant IL-37 displayed improved insulin sensitivity and obesity-induced inflammation [102].

Moreover, dietary FFA composition has been suggested to play an important role in insulin resistance and AT inflammation [26, 103, 104], with saturated FFAs promoting AT inflammation whereas omega-3 FFAs resolves the inflammatory response [105, 106].

The innate lymphoid cells (ILCs) are a lineage-negative subset of T cells (lacking the expression of surface markers that define other T cells) that act in response to the cytokines produced by surrounding macrophages, dendritic cells, and epithelial cells [107]. ILCs comprise five different subsets of immune cells: 1) natural killer (NK) cells, 2) ILC1s that produce interferon γ (IFN- γ), 3) ILC2s that produce IL-5 and IL-13, 4) lymphoid tissue inducer cells, and 5) ILC3s that produce IL-17 and IL-22 [107, 108]. These cells are suggested to regulate metabolism and to play a role in the development of obesity. NK cells and ILC1s are involved in the development of obesity-associated insulin resistance [109, 110], ILC2s are involved in the browning of the WAT and protection against obesity [111], ILC3s and lymphoid tissue inducer cells might be involved in the induction of obesity and obesity-associated insulin resistance due to lymphotoxin/IL-23/IL-22 activity [112].

Cell death and hypoxia also contribute to AT macrophage migration through the formation of “crown-like structures”, and the hypoxia hypothesis, respectively. Macrophages accumulate in the AT around adipocytes that are dead or in the process of dying, forming “crown-like structures” around the dead adipocytes [113]. These macrophages (M1 phenotype) produce a range of pro-inflammatory cytokines, such as TNF- α , which ultimately results in the development of metabolic disorders [114]. Moreover, macrophages localized in the “crown-like structures” in obese AT were shown to be enriched in Mincle (macrophage-inducible C-type lectin) [115]. The expression of Mincle correlated with the intensity of AT inflammation and ectopic lipid accumulation [116].

Their proliferation has IL-4/STAT6 as the driving force since IL-4 administration significantly enhanced the proliferation of ATMs in non-obese animals [117]. However, AT macrophages were recently suggested to be responsible for promoting the clearance of dead adipocytes through lysosomal exocytosis, also indicating their beneficial role [31]. Finally, the hypoxia hypothesis states that during obesity, angiogenesis is insufficient to maintain the vascularization and oxygenation necessary for AT proper function. Hypoxia activates the hypoxia-inducible factors (HIFs) which

can stimulate gene expression of proinflammatory pathway genes such as NK- κ B [118], affect AT macrophage polarization and inhibit preadipocyte differentiation [119]. The understanding of obesity and insulin resistance development from the AT perspective can be summarized through the interactions between adipokines, immune cells, cell death, and hypoxia.

Gut

The gut is a site of intricate immunological processes since it is the largest site of contact with antigens either from microbiota or from dietary factors. It also possesses the largest mass of lymphoid tissue in the organism. In the past decade, the number of investigations about immuno-metabolic interactions within the gut increased exponentially, especially due to strong evidence suggesting a direct association of the gut microbiota composition and its metabolites with the development of obesity and related metabolic disorders [120, 121].

Data show that caloric restriction and obesity affect gut permeability [122–124]. Standardized caloric restriction positively impacted gut permeability through a mechanism that remains unclear [122]. On the other hand, intestinal barrier impairment was shown to be exacerbated by a lipid challenge in obese patients [123], and anthropometric measurements and metabolic variables were shown to be positively correlated to increase in gut permeability during obesity [124]. The metabolites and byproducts generated by the microbiota also play an important role as components influencing inflammatory and metabolic processes as well as modulating the intestinal barrier function [125–127]. Molecules such as acetate, propionate, and butyrate – short-chain fatty acids (SCFAs) – produced as a result of the fermentation processes performed by the microbiota, can act as signaling and regulatory molecules involved in inflammation and insulin sensitivity [128–131]. Under non-obese conditions, SCFAs do not accumulate since they are transported through the portal vein, reaching the liver for clearance [132]. However, during obesity, the outcome of the increased barrier permeability is migration of products that usually remain in the intestinal environment, but which are now directed towards the systemic circulation at high concentrations. The problem associated with this migration is the recognition by the immune system of pathogen-associated molecular patterns (PAMPS), and lipopolysaccharides (LPS) in other tissues [133]. This recognition through toll-like receptors (TLRs) stimulates the proinflammatory response in insulin target tissues, contributing to reduced insulin sensitivity [134, 135]. On the one hand, excessive SCFAs

serve as an additional source of energy as well as an inflammatory factor in tissues such as the AT and liver. At the same time, they are involved in the β -cell glucose-stimulated insulin secretion through the G-protein coupled receptor 43 (GPR43)/GRPR41 [136, 137], and release of pancreatic peptide YY3-36 and glucagon-like peptide-1 (GLP-1) [138]. This suggests that the composition of the microbiota is responsible for the generation of a different type of SCFAs, which in turn are capable of triggering different regulatory cascades.

Germ-free animals enable greater insights to be gained into the impact of the microbiome in the metabolic homeostasis. These animals are resistant to the development of obesity and insulin resistance [139], concomitantly to the disruption of T and B cell function, and less efficient, impaired Tregs [140]. Obesity leads to dysbiosis [141], and it was recently suggested that this imbalance occurs even in a diet-independent fashion [142]. HFD affects not only the gut but also the gastric microbiota [143], and germ-free mice that are long-term exposed to a microbiota-derived from HFD animals develop dysglycemia and glucose intolerance [144]. An array of studies indicate that the diversity of the microbiota is closely associated with disease development and show that reduced diversity is positively correlated with inflammation and insulin resistance [145, 146]. For this reason, many efforts have been made to identify the potential differences between microbiota in health and disease [147].

Obesity stimulates the accumulation of non-beneficial bacterial strains, the conclusion made by experimental transfer of microbiota from obese to germ-free mice resulting in increased adiposity [148]. As a consequence of this imbalance, PAMPs and LPS stimulate a pro-inflammatory environment within the gut. High fat or high sugar diets were shown to induce imbalance in the ratio of specific strains of bacteria within the gut microbiota (*Firmicutes/Bacteroidetes*) and increase amounts of pro-inflammatory strains such as *Proteobacteria* [149, 150]. These alterations were partially restored by reverting to a regular chow diet [151]. Changes in the *Firmicutes/Bacteroidetes* ratio are associated not only with obesity (high F/B), but also with weight loss (low F/B) [152]. Obese and lean humans were found to display comparable altered taxonomic features [153]. *Lactobacillus* spp. are also affected. Rats that went through short- and long-term periods of caloric restriction displayed increased proliferation of this genus [154]. *Lactobacilli* are probiotics with mainly anti-inflammatory effects [155] capable of regulating Th17/Treg differentiation [156], altering the Th1/Th2 ratio [157], and suppressing macrophage WAT infiltration [158]. Under physiological

conditions, microbe-associated molecular patterns (MAMPS) stimulate the production of anti-inflammatory factors promoting tolerance and proper function of the intestinal barrier [159, 160]. On the other hand, during obesity (diet-induced), where the intestinal barrier is known to be more permeable [161], MAMPS stimulate intestinal epithelial cells, macrophages, and dendritic cells to produce pro-inflammatory cytokines [162]. The activation of inflammasomes is also suggested to contribute to gut microbiome perturbations [163, 164]. However, a recent rigorous microbial phylogenetic analysis performed in inflammasome-deficient mice failed to reproduce the gut microbiota composition alterations, raising the importance of careful experimental procedures and controls in evaluating results about the gut microbiota [165].

Over the last decade, the investigation of the interaction between the gut metabolism and the immune system has expanded our understanding about its impact on health and disease. Biomarkers to discriminate specific microbes' species will soon confirm or refute the direct role of bacterial strains in obesity, T2DM, metabolic disorders and cancers [166, 167]. Although the exact mechanisms are still not fully understood, dysbiosis has an impact on microbe and host metabolism, as well as shaping inflammatory responses. The complex crosstalk between the microbiota, intestinal permeability and inflammation that leads to insulin resistance, alterations in the glucose metabolism, and T2DM has already been reviewed by different authors [168–170]. Evidence accumulated so far opens the field for the future development of therapeutic strategies.

Skeletal muscle

The skeletal muscle (SM) is the primary site for dietary glucose uptake and storage in the form of glycogen, being, consequently, a crucial component affected during the development of insulin resistance [6]. The physiology behind how the SM takes up glucose is extensively investigated, with special attention to the insulin signaling cascade and glucose transporter 4 (GLUT4) translocation regulation [171, 172]. However, very little is known about the potential role of the immune system in this regulatory mechanism or how inflammation impacts muscle metabolism.

The very first link reporting immuno-metabolic interactions influencing muscle physiology was the observation that LPS, when injected into dogs, leads to insulin resistance caused by impairment of SM glucose uptake [173]. Years after, it was shown that, like the AT, the skeletal muscle of obese animals and humans can also generate TNF- α [174], and its attenuation was associated with improved insulin sensitivity and glucose me-

tabolism [175]. The JNK pathway is also involved, and its role in the pathogenesis of obesity-induced insulin resistance is well described [176, 177]. The mechanisms behind the protective effect of global JNK deficiency against diet-induced insulin resistance were carefully discussed previously [176]. While some studies have shown the SM-specific ablation of JNK results in an improvement of insulin resistance an improvement of insulin resistance [178–180], others indicate no impact [181, 182]. Thus, this immuno-metabolic interaction is still under discussion.

Similarly to the AT, many of the classical innate immune components play a role in the SM metabolism. The SM is characterized by a relatively low expression level of innate immune receptors [183]. Of all innate immune receptors, TLR4, 5, and 9 are the most abundant [184]. TLR4 activation stimulates glycolysis, inhibits fatty acid oxidation and induces insulin resistance [185]. Pharmacological inhibition of this receptor was shown to protect mice against diet-induced obesity [186]. While the whole-body deficiency of TLR5 causes increased fat mass, insulin resistance and metabolic syndrome-like features [187], the TLR5 SM-specific contribution remains unclear so far. The most recent update explains the role of TLR5 in smooth muscle and the development of atherosclerosis through activation of TLR5-dependent NADPH oxidases, and H₂O₂ generation [188]. TLR9, in turn, has been suggested to be involved in the development of type 1 diabetes [189], and despite being the most abundant TLR at the mRNA level in muscle, its role in SM metabolism is being investigated. The role of other TLRs has been extensively reviewed [183].

Although often neglected as a secretory tissue, myocytes can express and secrete myokines. The subset includes some cytokines (IL-6, IL-8, IL-15), fibroblast growth factor 21 (FGF21), basic FGF (FGF2), follistatin-related protein 1 (FSTL-1) and other molecules [190]. The myokine activity counterbalances the effects of the adipokines, stimulating beneficial effects on glucose and lipid metabolism and inflammation [190–192]. The SM-derived IL-6 is the most investigated myokine and, besides controversies [192], it is suggested to contribute to the metabolic homeostasis reestablishment upon exercise but not under basal conditions [193]. Moreover, IL-6 was reported to act in a gender-specific manner [194]. Mitochondrial dysfunction [195] and ER stress [196] trigger FGF21 secretion, but the relationship between FGF21-mediated metabolic alterations and disease progression is still not clear [197].

Altogether, the secretion of myokines does not seem to be the factor responsible for the development of muscular inflammation during obesity. Unlike in the AT, it is suggested that the in-

flammation in the muscles develops as a result of the production of proinflammatory molecules (adipokines) secreted from accumulated intermuscular and perimuscular fat depots and not by the tissue itself [198]. The obesity-induced increase of such fat storage sites is correlated with the development of a pro-inflammatory environment in the muscle [198], influencing insulin sensitivity by impairing its signaling as well as glucose uptake through the GLUT4 reduction [199].

Apparently, the skeletal muscle is more of a target of the inflammation induced by insulin resistance in other organs than, in fact, a site where this inflammation begins. The most accepted hypothesis is that free fatty acids (FFAs) stimulate the inflammatory response characterized by infiltration of T cells and macrophages with the involvement of the NLRP3 inflammasome [198, 200–202]. Likewise, it occurs in other tissues; macrophages in the SM polarize towards a proinflammatory phenotype during obesity [203]. Consequently, proinflammatory mediators such as TNF α , IFN- γ , and IL- β are shown to be augmented, while anti-inflammatory markers, such as IL-10, remain unaffected [204]. Similarly to AT, omega-3 FFAs were shown to restore SM insulin sensitivity and ameliorate lipotoxicity [205].

In summary, despite the muscle's ability to secrete myokines, the majority of the inflammatory molecules affecting its metabolism originate from the so-called perimuscular AT and not from the muscle itself. In the context of the immuno-metabolic interactions, the impact of SM has been under-investigated and the role of this communication and its implications for the development of metabolic diseases are still largely unknown.

Liver

The liver plays a crucial role in detoxification of xenobiotics, protein synthesis, carbohydrate household, lipid and protein metabolism, iron homeostasis, and secretion of hormones (IGF-1 and hepcidin). It is also known that the hepatic tissue is immunologically complex, being responsible for the production of cytokines, chemokines, and complement components, containing a diverse population of immune cells [206]. The hepatic immune system is regularly challenged with dietary factors of high inflammatory potential. The combination of constant metabolic activity and regular exposure to proinflammatory factors contributes to the state of chronic low-level inflammation of this organ [12]. Disruptions of this close immuno-metabolic interaction are associated with pathological inflammation that can lead to liver fibrosis, cancer, non-alcoholic fatty liver disease (NAFLD), obesity and other chronic diseases [207–210].

The liver displays two dominant types of macrophages: the Kupffer cells (KC) and the monocyte-derived macrophages [211]. Kupffer cells are liver-resident macrophages, comprising up to 90% of the total population of macrophages in the organism and around 25% of the whole subset of non-parenchymal cells in the organ [212]. In contrast to other macrophages, KC are prone to respond in a milder manner and are known to be able to secrete high concentrations of IL-10 [213]. Metabolic disorders do not impact KC in a quantitative way but impact their polarization states [214]. Under normal conditions, due to the tolerance required in the hepatic environment, KC tend to exhibit an M2-like phenotype [214]. On the other hand, because obesity and hepatic steatosis stimulate 1) secretion of higher levels of TGF- β and other proinflammatory cytokines [214], and 2) interaction between PPAR γ and NF- κ B [215] signaling pathways, KC are polarized towards a proinflammatory phenotype (M1). The imbalance in the M1/M2 ratio was shown to be restored in the HFD-induced NAFLD animal model upon treatment with rosiglitazone, a thiazolidinedione [216]. It indicates that PPAR γ modulation affects the interaction with NF- κ B, reducing M1 polarization and ameliorating hepatic steatosis [216]. It is suggested that TNF- α and IL-1 β are crucial players in the development of NAFLD and KC are the main generators of the first one in a process mediated by TLRs [217]. IL-1 β meanwhile was shown to be important for the progression of NAFLD to NASH [218].

Phenotypically different from KC is the other important group of macrophages found in the liver, the macrophages that are recruited to the organ – monocytes-derived macrophages [219]. These macrophages originate from blood monocytes and have CLEC5A as a specific marker, in contrast to the CD163 characteristic for the KC [220]. They are highly inflammatory, secrete a variety of cytokines (TNF- α , IL-1 β , IL-6, TGF β) [211] and reach the liver through the CCL2/CCR2 pathway [211]. During obesity, the excess of lipids in the AT promotes lipotoxicity, leading to liver damage and macrophage infiltration [201, 202, 221]. Again, the dietary composition of lipids may play an important role in this context, with omega-3 FFAs displaying interesting anti-inflammatory properties [222–224]. Along with the KC, these macrophages have been indicated as mediators of hepatic inflammation during obesity. The role of liver macrophages in the etiology of obesity/T2DM was established upon depletion of KC and macrophages in the liver resulted in prevention of steatosis, insulin resistance and inflammation [225].

Apart from the macrophages, neutrophils are also recruited to the liver during obesity [73] and contribute to the inflammatory process. As in

the AT, the release of neutrophil elastase in the hepatocytes leads to impairment of insulin sensitivity through IRS-2 degradation [73]. Neutrophils together with other cells such as infiltrated monocytes, endothelial cells, fibroblasts, mesenchymal cells, dendritic cells, and hepatocytes produce interferon gamma-induced protein 10 (IP-10), a proinflammatory cytokine associated with the presence of excess fat in the liver [226]. Liver lymphocyte imbalances during NAFLD and NASH were carefully described previously [227]. However, their role in the progression or development of obesity and T2DM has not yet been clearly defined. Decrease in CD4 $^{+}$ T cells [228], and increase in CD8 $^{+}$ T cell and NKT were linked to NAFLD and liver damage [229]. In addition, a gut-liver-intrahepatic CD8 $^{+}$ T cell axis was suggested [230]. This axis was demonstrated to have type 1 interferons as main drivers which provided a mechanism that could be the mediator between alterations in the gut microbiota and subsequent impairment in the insulin action and glucose metabolism during NAFLD and obesity [230].

Concerning the involvement of TLRs in the liver immuno-metabolic response, it is known that the lack of TLR4 protects mice from diet-induced insulin resistance and inflammation [186], and TLR4-deficient hepatocytes were suggested to be responsible for this effect. Mice with TLR4-deficient hepatocytes (Tlr4LKO C57BL/6) showed improvement in both insulin sensitivity and glucose tolerance in addition to steatosis amelioration after exposure to HFD [135].

Despite its central role, the lipotoxicity itself is not the only mediator of the hepatic inflammation. The rate of hepatocyte cell death also plays a role in the resulting proinflammatory environment during obesity and NAFLD. As a consequence of lipotoxicity, a significant loss of hepatocytes due to cell death was observed in the liver [231]. In this context, DAMPS are released and activate inflammasomes [232] which are critical in the progression of NAFLD to NASH. Liver inflammation that leads to disturbed hepatic insulin signaling was also described in wild type rats that after 9 weeks fed a high fructose diet displayed increased inhibitory phosphorylation of IRS-1, increased TNF- α gene expression, enhanced activation of NF- κ B [233]. Finally, a recent study demonstrated that liver macrophages produce a non-inflammatory factor named insulin-like growth factor-binding protein 7 (IGFBP7) that regulates liver metabolism [234]. It is suggested that activation of KC to a M1 phenotype does not seem to be required for the development of metabolic disease, indicating that the liver inflammation is, rather, resulted from the monocyte-derived macrophages. These new data places the liver macrophages as

strategic direct therapeutic targets in metabolic disease [234].

Pancreas

Composed of various cell types, the pancreas is divided in two distinct functional parts: 1) the exocrine pancreas, which secretes digestive enzymes that break down carbohydrates, lipids and proteins [235], and 2) the endocrine pancreas, that is a source of hormones such as insulin and glucagon which regulate glucose homeostasis [236]. Endocrine cells form pancreatic islets that, in humans, comprise of around 30% of α -cells (glucagon production), 60% β -cells (insulin production), and 10% of δ -cells (somatostatin production) and PP-cells (pancreatic polypeptide production [237, 238]. Immuno-metabolic interactions affect and modulate several internal processes within the islets, particularly concerning β -cells. These cells can sense plasma glucose concentration changes. Glucose is the major and sufficient stimulus for insulin secretion [239]. Failure of the glucose-stimulated insulin secretion is a hallmark of the development of T2DM and an important event in obesity-related conditions [240].

During obesity and metabolic malfunction where insulin resistance is present, β -cells undergo adaptations that stimulate their secretory activity in order to maintain metabolic homeostasis [241]. When those adaptations are insufficient, the excessive overload and demand for insulin lead to saturation and β -cell dysfunction [242]. Different mechanisms have been suggested to explain the β -cell failure in context of metabolic syndrome and T2DM, including, induction of oxidative stress, ER stress and mitochondrial dysfunction as well as imbalance in arachidonic acid metabolism [243–249]. These stress responses were related to mild islet inflammation, that was detected in pancreatic section of T2DM patients [250]. From the immunometabolic point of view, the three following mechanisms may participate in the inflammatory response within islets: 1) macrophage infiltration and/or activation of the tissue resident macrophages in pancreas and the generation of proinflammatory mediators [251], 2) the JNK activation and massive ER stress [176, 252], and 3) intra-islet amyloid polypeptide (IAPP) deposits formation and activation of inflammasomes [253–257]. All of them were excellently reviewed in [258]. Exposure to 30 mM glucose of human EndoC- β H1 β -cells did not stimulate IL-1 β gene or protein expression [259, 260]. Therefore, it remains controversial whether or not pancreatic β -cells can produce IL-1 β , though one cannot exclude the possibility that the T2DM environment with a uniquely composed mixture of various proinflammatory and nutrient factors

may induce cytokine production or maturation within β -cells *in vivo*. Though the anti-IL-1 β targeted therapeutic approaches for T2DM resulted in inconsistent outcomes in terms of pancreatic β -cell function protection [261–263], they were shown to reduce serum CRP levels and to promote cardioprotection [257]. Other anti-inflammatory interventions resulted in rather modest protection as discussed in detail in [250].

Similar to other tissues, macrophages infiltration was shown to be increased in islets during T2DM and obesity [264, 265]. Evidence shows that the number of macrophages positively correlates with the severity of pancreatic dysfunction [265, 266] and that infiltrating macrophages exhibit a proinflammatory phenotype [267], suggesting a role for these cells in the progression of β -cell failure. At the same time, another study placed monocyte-derived macrophages as responsible for these events [268], while yet other reports demonstrated that instead resident macrophages play a role [269]. A recent study unraveled the phenotypes and functional specifications of these immune cells in the islets [270]. The authors state that during obesity the islet inflammation is dominated by macrophages, and emphasize the role of the islets-resident macrophages in the immunopathology of the β -cell failure. Immunostaining and RNA-sequencing of pancreatic islets from obese and lean mice showed intra- and peri-islet resident macrophages, being the islets from obese animals rich in CD11c⁺ macrophages (intra-islet macrophages). Functionally, these intra-islets macrophages were shown to diminish β -cell insulin production and to engulf insulin secretory granules contributing to insulin secretion impairment [270]. Although well-known by a negative impact on glucose-stimulated insulin secretion, a recent study showed that intra- and peri-islet macrophages populations from obese mice stimulated β -cell proliferation in a mechanism dependent on the platelet-derived growth receptor (PDGFR) [270]. Potential differences in the subtypes of islets-macrophages that might play this dual role have not yet been described, as well as whether this feature can be found also in human islets.

Interestingly, the classical inflammatory response pathway of arachidonic acid metabolism is present in β -cells and undergoes significant changes under diabetogenic conditions [246–249]. Pancreatic β -cells are characterized by an imbalance in the expression profile of enzymes involved in the arachidonic acid cascade with the weak expression of prostacyclin synthase expression, responsible for the generation of the anti-inflammatory prostacyclin (prostaglandin I₂) [249–271]. The proinflammatory prostaglandin E₂ was shown

to reduce glucose-induced insulin secretion [248]. In contrast, the anti-inflammatory prostacyclin is a strong potentiator of insulin secretion [249]. Prostaglandin synthesis inhibitors [272] as well as prostacyclin analog beraprost sodium [273] were shown to ameliorate characteristics of metabolic syndrome in obese Zucker fatty rats and to improve insulin secretion in diabetic patients, respectively.

Recent studies evaluated the protective potential of omega-3 FFAs for lowering of inflammation *via* formation of SPMs in T2DM and obesity animal models and diabetic patients with various outcomes [25, 274]. While the role of SPMs in islet inflammation in T2DM remains currently unknown, SPMs have been shown to promote M2 polarization of macrophages, reduce AT and muscle inflammation, increase insulin sensitivity and lower fasting blood glucose in diet-induced obese mice, *ob/ob* mice or obese-diabetic mice [26, 275–277].

Further investigations are needed to better elucidate the immuno-metabolic interactions within pancreatic islets and to explore the therapeutic potential of anti-inflammatory metabolites of arachidonic acid cascade.

In conclusion, immunometabolism is an emerging field that investigates the relationship between metabolic and inflammatory processes. These investigations are of special interest to clarify how metabolic disorders develop and progress. Inter- and intra-organ interactions were presented using the most updated reports in the field and summarized in Figure 1. The review indicates that many studies are still needed to uncover the molecular mechanisms behind this cross-talk that influences central organs responsible for the whole-body homeostasis.

T2DM and obesity are disorders in which inflammation plays an important role in the pathogenesis. How does inflammation become so harmful to the point of causing or worsening metabolic disorders? The discussed data brings the innate immune cells, especially macrophages, as big players in secreting proinflammatory factors that directly impair metabolic tissue functions. Besides some particularities, the adaptive immune response (consequently activated) and proinflammatory pathways such as JNK and NF- κ B are also important contributors to the inflammatory environment in multiple organs. In the AT, B-regs and cytokines, such as IL-37, represent potential therapeutic targets. In the gut, the modulation of the intestinal barrier permeability and clarifications of the impact of dysbiosis will bring important discoveries. In the liver, much is still mysterious about the impact of its resident macrophages. In the muscle the intriguing dysregulation of myokine production and formation of intramuscular fat depots require further investigations. Finally, mild, but persistent,

and largely still under investigated inflammation of pancreatic islets may open new therapeutic possibilities to preserve proper β -cell function.

Besides many exciting and promising discoveries that unravel mechanisms particularly important to obesity and diabetes, it is important to emphasize a challenge: the translation of the knowledge to the human situation and the arising limitations. Inter-individual variability in humans influences the type of immune response and its magnitude [278]. It translates into a major challenge in the development of therapies that do not harm the immune system as a whole. Cross studies, genetic variations, and environmental considerations will be prerequisite to make the translation a reality. Finally, the role of inflammation in the maintenance of homeostasis and protection against infections and injuries should not be neglected. Despite the elucidation of new players and their interactions in the immuno-metabolic crosstalk, translating them to therapeutic targets may compromise the body's ability to defend itself. Future investigations should uncover not only new mechanisms involved but also provide answers on how to apply them in order to treat and cure metabolic diseases.

Conflict of interest

The authors declare no conflict of interest.

References

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; 384: 766-81.
2. Oh TJ, Moon JH, Choi SH, et al. Body-weight fluctuation and incident diabetes mellitus, cardiovascular disease, and mortality: a 16-year prospective cohort study. *J Clin Endocrinol Metab* 2019; 104: 639-46.
3. Peltonen M, Carlsson LM. Body fatness and cancer. *N Engl J Med* 2016; 375: 2007-8.
4. Walsh TP, Arnold JB, Evans AM, Yaxley A, Damarell RA, Shanahan EM. The association between body fat and musculoskeletal pain: a systematic review and meta-analysis. *BMC Musculoskelet Disord* 2018; 19: 233.
5. Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. *Nat Rev Endocrinol* 2019; 15: 261-73.
6. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care* 2009; 32 Suppl 2: S157-63.
7. Lee YS, Wollam J, Olefsky JM. An integrated view of immunometabolism. *Cell* 2018; 172: 22-40.
8. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. *Nature* 2017; 542: 177-85.
9. Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF- α or its receptors. *Diabetologia* 2002; 45: 805-12.

10. Ligthart S, Marzi C, Aslibekyan S, et al. DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases. *Genome Biol* 2016; 17: 255.
11. Henson J, Yates T, Edwardson CL, et al. Sedentary time and markers of chronic low-grade inflammation in a high risk population. *PLoS One* 2013; 8: e78350.
12. Caputo T, Gilardi F, Desvergne B. From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. *FEBS Lett* 2017; 591: 3061-88.
13. Kohlgruber AC, Gal-Oz ST, LaMarche NM, et al. Gamma-delta T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. *Nat Immunol* 2018; 19: 464-74.
14. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. *Nat Med* 2009; 15: 930-9.
15. Herder C, Brunner EJ, Rathmann W, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. *Diabetes Care* 2009; 32: 421-3.
16. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003; 112: 1821-30.
17. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. *Arch Med Sci* 2017; 13: 851-63.
18. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science* 1993; 259: 87-91.
19. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF- α function. *Nature* 1997; 389: 610-4.
20. Boden G, Song W, Duan X, et al. Infusion of glucose and lipids at physiological rates causes acute endoplasmic reticulum stress in rat liver. *Obesity (Silver Spring)* 2011; 19: 1366-73.
21. Boden G. Obesity, insulin resistance and free fatty acids. *Curr Opin Endocrinol Diabetes Obes* 2011; 18: 139-43.
22. Boden G, Merali S. Measurement of the increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. *Methods Enzymol* 2011; 489: 67-82.
23. Atwa H, Gad K, Hagrasy H, et al. Is subclinical atherosclerosis associated with visceral fat and fatty liver in adolescents with type 1 diabetes? *Arch Med Sci* 2018; 14: 1355-60.
24. Wanders AJ, Blom WAM, Zock PL, Geleijnse JM, Brouwer IA, Alsema M. Plant-derived polyunsaturated fatty acids and markers of glucose metabolism and insulin resistance: a meta-analysis of randomized controlled feeding trials. *BMJ Open Diabetes Res Care* 2019; 7: e000585.
25. Serhan CN. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. *FASEB J* 2017; 31: 1273-88.
26. Martinez-Fernandez L, Gonzalez-Muniesa P, Laiglesia LM, et al. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. *FASEB J* 2017; 31: 2135-45.
27. Apovian CM, Bigornia S, Mott M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. *Arterioscler Thromb Vasc Biol* 2008; 28: 1654-9.
28. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest* 2007; 117: 175-84.
29. Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization in inflammation during infectious diseases. *Int J Mol Sci* 2018; 19: E1801.
30. Kratz M, Coats BR, Hisert KB, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. *Cell Metab* 2014; 20: 614-25.
31. Coats BR, Schoenfelt KQ, Barbosa-Lorenzi VC, et al. Metabolically activated adipose tissue macrophages perform detrimental and beneficial functions during diet-induced obesity. *Cell Rep* 2017; 20: 3149-61.
32. Desai HR, Sivasubramaniyam T, Revelo XS, et al. Macrophage JAK2 deficiency protects against high-fat diet-induced inflammation. *Sci Rep* 2017; 7: 7653.
33. Finucane OM, Reynolds CM, McGillicuddy FC, et al. Macrophage migration inhibitory factor deficiency ameliorates high-fat diet induced insulin resistance in mice with reduced adipose inflammation and hepatic steatosis. *PLoS One* 2014; 9: e113369.
34. Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. *Ann Intern Med* 2010; 152: 346-57.
35. Oral EA, Reilly SM, Gomez AV, et al. Inhibition of IKK α -repressin and TBK1 improves glucose control in a subset of patients with type 2 diabetes. *Cell Metab* 2017; 26: 157-170 e7.
36. Fasshauer M, Bluher M. Adipokines in health and disease. *Trends Pharmacol Sci* 2015; 36: 461-70.
37. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. *Arch Med Sci* 2013; 9: 191-200.
38. Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. *J Intern Med* 2016; 280: 465-75.
39. Mandrup-Poulsen T. Metabolism and the inflammasome in health and ageing. *Nat Rev Endocrinol* 2017; 14: 72.
40. Ghigliotti G, Barisione C, Garibaldi S, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. *Inflammation* 2014; 37: 1337-53.
41. Boutens L, Stienstra R. Adipose tissue macrophages: going off track during obesity. *Diabetologia* 2016; 59: 879-94.
42. Castoldi A, Naffah de Souza C, Câmara NOS, Moraes-Vieira PM. The macrophage switch in obesity development. *Front Immunol* 2016; 6: 637.
43. Thomas D, Apovian C. Macrophage functions in lean and obese adipose tissue. *Metabolism* 2017; 72: 120-43.
44. Correa LH, Heyn GS, Magalhaes KG. The impact of the adipose organ plasticity on inflammation and cancer progression. *Cells* 2019; 8: E662.
45. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J Lipid Res* 2005; 46: 2347-55.
46. Strissel KJ, Stancheva Z, Miyoshi H, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. *Diabetes* 2007; 56: 2910-8.
47. Giordano A, Murano I, Mondini E, et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. *J Lipid Res* 2013; 54: 2423-36.
48. Trim W, Turner JE, Thompson D. Parallels in immunometabolic adipose tissue dysfunction with ageing and obesity. *Front Immunol* 2018; 9: 169.
49. Suárez-Cuenca JA, Ruíz-Hernández AS, Mendoza-Castañeda AA, et al. Neutrophil-to-lymphocyte ratio and its

- relation with pro-inflammatory mediators, visceral adiposity and carotid intima-media thickness in population with obesity. *Eur J Clin Invest* 2019; 49: e13085.
50. Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. *Arch Med Sci* 2015; 11: 463-82.
 51. Correa LH, Correa R, Farinasso CM, de Sant'Ana Dourado LP, Magalhaes KG. Adipocytes and macrophages interplay in the orchestration of tumor microenvironment: new implications in cancer progression. *Front Immunol* 2017; 8: 1129.
 52. Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. *J Endocrinol* 2014; 222: R113-27.
 53. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest* 2003; 112: 1796-808.
 54. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. *J Clin Invest* 2006; 116: 115-24.
 55. Koppaka S, Kehlenbrink S, Carey M, et al. Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. *Diabetes* 2013; 62: 1843-54.
 56. Fjeldborg K, Pedersen SB, Moller HJ, Christiansen T, Benntzen M, Richelsen B. Human adipose tissue macrophages are enhanced but changed to an anti-inflammatory profile in obesity. *J Immunol Res* 2014; 2014: 309548.
 57. Tourniaire F, Romier-Crouzet B, Lee JH, et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-kappaB. *PLoS One* 2013; 8: e66515.
 58. Park SH, Liu Z, Sui Y, et al. IKKbeta is essential for adipocyte survival and adaptive adipose remodeling in obesity. *Diabetes* 2016; 65: 1616-29.
 59. Holzer RG, Park EJ, Li N, et al. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. *Cell* 2011; 147: 173-84.
 60. Chaudhuri R, Krycer JR, Fazakerley DJ, et al. The transcriptional response to oxidative stress is part of, but not sufficient for, insulin resistance in adipocytes. *Sci Rep* 2018; 8: 1774.
 61. Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. *Cold Spring Harb Perspect Biol* 2014; 6: a009191.
 62. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. *Inflamm Res* 2009; 58: 727-36.
 63. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest* 2006; 116: 1793-801.
 64. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. *J Clin Endocrinol Metab* 2000; 85: 3338-42.
 65. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. *J Biol Chem* 2003; 278: 13740-6.
 66. Matthews VB, Allen TL, Risis S, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. *Diabetologia* 2010; 53: 2431-41.
 67. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. *Nat Med* 2002; 8: 75-9.
 68. Abella V, Scotece M, Conde J, et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. *Nat Rev Rheumatol* 2017; 13: 100-9.
 69. Bai Y, Sun Q. Macrophage recruitment in obese adipose tissue. *Obes Rev* 2015; 16: 127-36.
 70. Batra A, Okur B, Glaben R, et al. Leptin: a critical regulator of CD4+ T-cell polarization in vitro and in vivo. *Endocrinology* 2010; 151: 56-62.
 71. Saucillo DC, Gerriets VA, Sheng J, Rathmell JC, Maciver NJ. Leptin metabolically licenses T cells for activation to link nutrition and immunity. *J Immunol* 2014; 192: 136-44.
 72. Gerriets VA, Danzaki K, Kishton RJ, et al. Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. *Eur J Immunol* 2016; 46: 1970-83.
 73. Talukdar S, Oh DY, Bandyopadhyay G, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. *Nat Med* 2012; 18: 1407-12.
 74. Kawanishi N, Niihara H, Mizokami T, Yada K, Suzuki K. Exercise training attenuates neutrophil infiltration and elastase expression in adipose tissue of high-fat-diet-induced obese mice. *Physiol Rep* 2015; 3: e12534.
 75. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. *Immunity* 2014; 41: 36-48.
 76. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. *Nat Med* 2009; 15: 914-20.
 77. van der Weerd K, Dik WA, Schrijver B, et al. Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg- and Th2-dominated phenotype. *Diabetes* 2012; 61: 401-8.
 78. Xia C, Rao X, Zhong J. Role of T lymphocytes in type 2 diabetes and diabetes-associated inflammation. *J Diabetes Res* 2017; 2017: 6494795.
 79. Kintscher U, Hartge M, Hess K, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue. *Arterioscler Thromb Vasc Biol* 2008; 28: 1304-10.
 80. Misumi I, Starmer J, Uchimura T, Beck MA, Magnuson T, Whitmire JK. Obesity expands a distinct population of T cells in adipose tissue and increases vulnerability to infection. *Cell Rep* 2019; 27: 514-524.e5.
 81. Shirakawa K, Yan X, Shinmura K, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. *J Clin Invest* 2016; 126: 4626-39.
 82. Deng T, Lyon CJ, Minze LJ, et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. *Cell Metab* 2013; 17: 411-22.
 83. Zuniga LA, Shen WJ, Joyce-Shaikh B, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. *J Immunol* 2010; 185: 6947-59.
 84. Mehta P, Nuotio-Antar AM, Smith CW. Gammadelta T cells promote inflammation and insulin resistance during high fat diet-induced obesity in mice. *J Leukoc Biol* 2015; 97: 121-34.
 85. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. *Cell* 2014; 156: 20-44.
 86. West-Eberhard MJ. Nutrition, the visceral immune system, and the evolutionary origins of pathogenic obesity. *Proc Natl Acad Sci USA* 2019; 116: 723-31.
 87. Lu J, Zhao J, Meng H, Zhang X. Adipose tissue-resident immune cells in obesity and type 2 diabetes. *Front Immunol* 2019; 10: 1173.
 88. McLaughlin T, Liu LF, Lamendola C, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. *Arterioscler Thromb Vasc Biol* 2014; 34: 2637-43.

89. Wang Q, Wu H. T cells in adipose tissue: critical players in immunometabolism. *Front Immunol* 2018; 9: 2509.
90. Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. *Nat Med* 2009; 15: 921-9.
91. Bapat SP, Myoung Suh J, Fang S, et al. Depletion of fat-resident Treg cells prevents age-associated insulin resistance. *Nature* 2015; 528: 137-41.
92. Deng T, Liu J, Deng Y, et al. Adipocyte adaptive immunity mediates diet-induced adipose inflammation and insulin resistance by decreasing adipose Treg cells. *Nature Communications* 2017; 8: 15725.
93. Shao S, He F, Yang Y, Yuan G, Zhang M, Yu X. Th17 cells in type 1 diabetes. *Cell Immunol* 2012; 280: 16-21.
94. Wang M, Chen F, Wang J, Zeng Z, Yang Q, Shao S. Th17 and Treg lymphocytes in obesity and type 2 diabetic patients. *Clin Immunol* 2018; 197: 77-85.
95. Duffaut C, Galitzky J, Lafontan M, Bouloumié A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. *Biochem Biophys Res Commun* 2009; 384: 482-5.
96. Frasca D, Diaz A, Romero M, Vazquez T, Blomberg BB. Obesity induces pro-inflammatory B cells and impairs B cell function in old mice. *Mech Ageing Dev* 2017; 162: 91-9.
97. Ying W, Wollam J, Ofrecio JM, et al. Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling. *J Clin Invest* 2017; 127: 1019-30.
98. Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. *Nat Med* 2011; 17: 610-7.
99. Nishimura S, Manabe I, Takaki S, et al. Adipose natural regulatory B cells negatively control adipose tissue inflammation. *Cell Metab* 2013; 18: 759-66.
100. García-Hernández MH, Rodríguez-Varela E, García-Jacobo RE, et al. Frequency of regulatory B cells in adipose tissue and peripheral blood from individuals with overweight, obesity and normal-weight. *Obes Rev Clin Pract* 2018; 12: 513-9.
101. Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. *Nat Commun* 2014; 5: 4711.
102. Ballak DB, Li S, Cavalli G, et al. Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. *J Biol Chem* 2018; 293: 14224-36.
103. de Araújo Lopes A, da Fonseca FN, Rocha TM, et al. Eugenol as a promising molecule for the treatment of dermatitis: antioxidant and anti-inflammatory activities and its nanoformulation. *Oxid Med Cell Longev* 2018; 2018: 8194849.
104. Titos E, Rius B, Lopez-Vicario C, et al. Signaling and immunoresolving actions of resolvin D1 in inflamed human visceral adipose tissue. *J Immunol* 2016; 197: 3360-70.
105. Flock MR, Rogers CJ, Prabhu KS, Kris-Etherton PM. Immunometabolic role of long-chain omega-3 fatty acids in obesity-induced inflammation. *Diabetes Metab Res Rev* 2013; 29: 431-45.
106. Gonzalez-Periz A, Claria J. Resolution of adipose tissue inflammation. *Sci World J* 2010; 10: 832-56.
107. Artis D, Spits H. The biology of innate lymphoid cells. *Nature* 2015; 517: 293-301.
108. Vivier E, Artis D, Colonna M, et al. Innate lymphoid cells: 10 years on. *Cell* 2018; 174: 1054-66.
109. O'Sullivan TE, Rapp M, Fan X, et al. Adipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance. *Immunity* 2016; 45: 428-41.
110. Wensveen FM, Jelencic V, Valentic S, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. *Nat Immunol* 2015; 16: 376-85.
111. Brestoff JR, Kim BS, Saenz SA, et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. *Nature* 2015; 519: 242-6.
112. Saetang J, Sangkhathat S. Role of innate lymphoid cells in obesity and metabolic disease (Review). *Mol Med Rep* 2018; 17: 1403-12.
113. Murano I, Barbatelli G, Parisani V, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. *J Lipid Res* 2008; 49: 1562-8.
114. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. *Cell* 2013; 152: 673-84.
115. Tanaka M, Ikeda K, Suganami T, et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. *Nat Commun* 2014; 5: 4982.
116. Tanaka E, Asanuma K, Kim E, et al. Notch2 activation ameliorates nephrosis. *Nat Commun* 2014; 5: 3296.
117. Zheng C, Yang Q, Cao J, et al. Local proliferation initiates macrophage accumulation in adipose tissue during obesity. *Cell Death Dis* 2016; 7: e2167.
118. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. *Diabetes* 2007; 56: 901-11.
119. Engin A. Adipose tissue hypoxia in obesity and its impact on preadipocytes and macrophages: hypoxia hypothesis. *Adv Exp Med Biol* 2017; 960: 305-26.
120. Luck H, Tsai S, Chung J, et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. *Cell Metab* 2015; 21: 527-42.
121. Monteiro-Sepulveda M, Touch S, Mendes-Sa C, et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. *Cell Metab* 2015; 22: 113-24.
122. Ott B, Skurk T, Hastreiter L, et al. Effect of caloric restriction on gut permeability, inflammation markers, and fecal microbiota in obese women. *Sci Rep* 2017; 7: 11955.
123. Genser L, Aguanno D, Soula HA, et al. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. *J Pathol* 2018; 246: 217-30.
124. Teixeira TFS, Souza NCS, Chiarello PG, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. *Clin Nutr* 2012; 31: 735-40.
125. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 2013; 504: 446-50.
126. Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. *Cell* 2015; 163: 367-80.
127. Fabbiano S, Suarez-Zamorano N, Chevalier C, et al. Functional gut microbiota remodeling contributes to the caloric restriction-induced metabolic improvements. *Cell Metab* 2018; 28: 907-21.e7.
128. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. *Nat Rev Endocrinol* 2015; 11: 577-91.
129. Jocken JWE, Gonzalez Hernandez MA, Hoebbers NTH, et al. Short-chain fatty acids differentially affect intracellular lipolysis in a human white adipocyte model. *Front Endocrinol (Lausanne)* 2017; 8: 372.
130. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. *Aliment Pharmacol Ther* 2008; 27: 104-19.

131. Gaudier E, Rival M, Buisine MP, Robineau I, Hoebler C. Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. *Physiol Res* 2009; 58: 111-9.
132. Stumpff F. A look at the smelly side of physiology: transport of short chain fatty acids. *Pflugers Arch* 2018; 470: 571-98.
133. Hersoug LG, Moller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. *Obes Rev* 2016; 17: 297-312.
134. Pekkala S, Munukka E, Kong L, et al. Toll-like receptor 5 in obesity: the role of gut microbiota and adipose tissue inflammation. *Obesity (Silver Spring)* 2015; 23: 581-90.
135. Jia L, Vianna CR, Fukuda M, et al. Hepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. *Nat Commun* 2014; 5: 3878.
136. Pingitore A, Gonzalez-Abuin N, Ruz-Maldonado I, Huang GC, Frost G, Persaud SJ. Short chain fatty acids stimulate insulin secretion and reduce apoptosis in mouse and human islets in vitro: role of free fatty acid receptor 2. *Diabetes Obes Metab* 2019; 21: 330-9.
137. Veprik A, Laufer D, Weiss S, Rubins N, Walker MD. GPR41 modulates insulin secretion and gene expression in pancreatic beta-cells and modifies metabolic homeostasis in fed and fasting states. *FASEB J* 2016; 30: 3860-9.
138. Christiansen CB, Gabe MBN, Svendsen B, Dragsted LO, Rosenkilde MM, Holst JJ. The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. *Am J Physiol Gastrointest Liver Physiol* 2018; 315: G53-G65.
139. Rabot S, Membrez M, Bruneau A, et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. *FASEB J* 2010; 24: 4948-59.
140. Ostman S, Rask C, Wold AE, Hultkrantz S, Telemo E. Impaired regulatory T cell function in germ-free mice. *Eur J Immunol* 2006; 36: 2336-46.
141. Backhed F, Manchester JK, Semenkovich CF, Gordon JL. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc Natl Acad Sci USA* 2007; 104: 979-84.
142. Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. *J Diabetes Res* 2018; 2018: 3462092.
143. He C, Cheng D, Peng C, Li Y, Zhu Y, Lu N. High-fat diet induces dysbiosis of gastric microbiota prior to gut microbiota in association with metabolic disorders in mice. *Front Microbiol* 2018; 9: 639.
144. Foley KP, Zlitni S, Denou E, et al. Long term but not short term exposure to obesity related microbiota promotes host insulin resistance. *Nat Commun* 2018; 9: 4681.
145. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature* 2013; 500: 541-6.
146. Gong D, Gong X, Wang L, Yu X, Dong Q. Involvement of reduced microbial diversity in inflammatory bowel disease. *Gastroenterol Res Pract* 2016; 2016: 6951091.
147. Human Microbiome Project Consortium. A framework for human microbiome research. *Nature* 2012; 486: 215-21.
148. Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. *ISME J* 2013; 7: 880-4.
149. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. *Gastroenterology* 2009; 137: 1716-24.
150. Kiilerich P, Myrmet LS, Fjaere E, et al. Effect of a long-term high-protein diet on survival, obesity development, and gut microbiota in mice. *Am J Physiol Endocrinol Metab* 2016; 310: E886-E99.
151. Shang Y, Khafipour E, Derakhshani H, et al. Short term high fat diet induces obesity-enhancing changes in mouse gut microbiota that are partially reversed by cessation of the high fat diet. *Lipids* 2017; 52: 499-511.
152. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JL. Obesity alters gut microbial ecology. *Proceed Nat Acad Sci USA* 2005; 102: 11070-5.
153. Bervoets L, Van Hoorenbeeck K, Kortleven I, et al. Differences in gut microbiota composition between obese and lean children: a cross-sectional study. *Gut Pathog* 2013; 5: 10.
154. Fraumene C, Manghina V, Cadoni E, et al. Caloric restriction promotes rapid expansion and long-lasting increase of Lactobacillus in the rat fecal microbiota. *Gut Microbes* 2018; 9: 104-14.
155. Ding YH, Qian LY, Pang J, et al. The regulation of immune cells by Lactobacilli: a potential therapeutic target for anti-atherosclerosis therapy. *Oncotarget* 2017; 8: 59915-59928.
156. Wang K, Dong H, Qi Y, et al. Lactobacillus casei regulates differentiation of Th17/Treg cells to reduce intestinal inflammation in mice. *Can J Vet Res* 2017; 81: 122-8.
157. Smelt MJ, de Haan BJ, Bron PA, et al. Probiotics can generate FoxP3 T-cell responses in the small intestine and simultaneously inducing CD4 and CD8 T cell activation in the large intestine. *PLoS One* 2013; 8: e68952.
158. Ukibe K, Miyoshi M, Kadooka Y. Administration of Lactobacillus gasseri SBT2055 suppresses macrophage infiltration into adipose tissue in diet-induced obese mice. *Br J Nutr* 2015; 114: 1180-7.
159. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 2013; 341: 569-73.
160. Pandiyan P, Bhaskaran N, Zou M, Schneider E, Jayaraman S, Huehn J. Microbiome dependent regulation of Tregs and Th17 cells in mucosa. *Front Immunol* 2019; 10: 426.
161. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* 2008; 57: 1470-81.
162. Maynard CL, Elson CO, Hattori RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. *Nature* 2012; 489: 231-41.
163. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. *Cell* 2011; 145: 745-57.
164. Pierantonelli I, Rychlicki C, Agostinelli L, et al. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. *Sci Rep* 2017; 7: 12200.
165. Mamantopoulos M, Ronchi F, Van Hauwermeiren F, et al. Nlrp6- and ASC-dependent inflammasomes do not shape the commensal gut microbiota composition. *Immunity* 2017; 47: 339-348.e4.
166. Rajpoot M, Sharma AK, Sharma A, Gupta GK. Understanding the microbiome: emerging biomarkers for exploiting the microbiota for personalized medicine against cancer. *Semin Cancer Biol* 2018; 52 (Pt 1): 1-8.
167. Del Chierico F, Abbatini F, Russo A, et al. Gut microbiota markers in obese adolescent and adult patients:

- age-dependent differential patterns. *Front Microbiol* 2018; 9: 1210.
168. Crommen S, Simon MC. Microbial regulation of glucose metabolism and insulin resistance. *Genes (Basel)* 2017; 9: E10.
 169. Allin KH, Nielsen T, Pedersen O. Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. *Eur J Endocrinol* 2015; 172: R167-R177.
 170. Aydin O, Nieuwdorp M, Gerdes V. The gut microbiome as a target for the treatment of type 2 diabetes. *Curr Diab Rep* 2018; 18: 55.
 171. Tunduguru R, Thurmond DC. Promoting glucose transporter-4 vesicle trafficking along cytoskeletal tracks: PAK-ing them out. *Front Endocrinol (Lausanne)* 2017; 8: 329.
 172. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. *Physiol Rev* 2013; 93: 993-1017.
 173. Raymond RM, Harkema JM, Emerson TE Jr. In vivo skeletal muscle insulin resistance during *E. coli* endotoxin shock in the dog. *Circ Shock* 1981; 8: 425-33.
 174. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. *J Clin Invest* 1996; 97: 1111-6.
 175. Borst SE, Bagby GJ. Neutralization of tumor necrosis factor reverses age-induced impairment of insulin responsiveness in skeletal muscle of Sprague-Dawley rats. *Metabolism* 2002; 51: 1061-4.
 176. Solinas G, Becattini B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. *Mol Metab* 2017; 6: 174-84.
 177. Han MS, Jung DY, Morel C, et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. *Science* 2013; 339: 218-22.
 178. Sabio G, Kennedy NJ, Cavanagh-Kyros J, et al. Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulin resistance. *Mol Cell Biol* 2010; 30: 106-15.
 179. Yan H, Gao Y, Zhang Y. Inhibition of JNK suppresses autophagy and attenuates insulin resistance in a rat model of nonalcoholic fatty liver disease. *Mol Med Rep* 2017; 15: 180-6.
 180. Henstridge DC, Bruce CR, Pang CP, et al. Skeletal muscle-specific overproduction of constitutively activated c-Jun N-terminal kinase (JNK) induces insulin resistance in mice. *Diabetologia* 2012; 55: 2769-78.
 181. Witzczak CA, Hirshman MF, Jessen N, et al. JNK1 deficiency does not enhance muscle glucose metabolism in lean mice. *Biochem Biophys Res Commun* 2006; 350: 1063-8.
 182. Pal M, Wunderlich CM, Spohn G, Bronneke HS, Schmidt-Supprian M, Wunderlich FT. Alteration of JNK-1 signaling in skeletal muscle fails to affect glucose homeostasis and obesity-associated insulin resistance in mice. *PLoS One* 2013; 8: e54247.
 183. Pillon NJ, Krook A. Innate immune receptors in skeletal muscle metabolism. *Exp Cell Res* 2017; 360: 47-54.
 184. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. *Biol Pharm Bull* 2005; 28: 886-92.
 185. Frisard MI, McMillan RP, Marchand J, et al. Toll-like receptor 4 modulates skeletal muscle substrate metabolism. *Am J Physiol Endocrinol Metab* 2010; 298: E988-98.
 186. Zhang N, Liang H, Farese RV, Li J, Musi N, Hussey SE. Pharmacological TLR4 inhibition protects against acute and chronic fat-induced insulin resistance in rats. *PLoS One* 2015; 10: e0132575.
 187. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science* 2010; 328: 228-31.
 188. Kim J, Seo M, Kim SK, Bae YS. Flagellin-induced NADPH oxidase 4 activation is involved in atherosclerosis. *Sci Rep* 2016; 6: 25437.
 189. Liu M, Peng J, Tai N, et al. Toll-like receptor 9 negatively regulates pancreatic islet beta cell growth and function in a mouse model of type 1 diabetes. *Diabetologia* 2018; 61: 2333-43.
 190. Lightfoot AP, Cooper RG. The role of myokines in muscle health and disease. *Curr Opin Rheumatol* 2016; 28: 661-6.
 191. Ye J. Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes. *Front Med* 2015; 9: 139-45.
 192. Belizario JE, Fontes-Oliveira CC, Borges JP, Kashiabara JA, Vannier E. Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6. *Springerplus* 2016; 5: 619.
 193. Knudsen JG, Gudiksen A, Bertholdt L, et al. Skeletal muscle IL-6 regulates muscle substrate utilization and adipose tissue metabolism during recovery from an acute bout of exercise. *PLoS One* 2017; 12: e0189301.
 194. Molinero A, Fernandez-Perez A, Mogas A, et al. Role of muscle IL-6 in gender-specific metabolism in mice. *PLoS One* 2017; 12: e0173675.
 195. Keipert S, Ost M, Johann K, et al. Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. *Am J Physiol Endocrinol Metab* 2014; 306: E469-82.
 196. Montgomery MK, Mokhtar R, Bayliss J, et al. Perilipin 5 deletion unmasks an endoplasmic reticulum stress-fibroblast growth factor 21 axis in skeletal muscle. *Diabetes* 2018; 67: 594-606.
 197. Tezze C, Romanello V, Sandri M. FGF21 as modulator of metabolism in health and disease. *Front Physiol* 2019; 10: 419.
 198. Khan IM, Perrard XY, Brunner G, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. *Int J Obes (Lond)* 2015; 39: 1607-18.
 199. Nicholson T, Church C, Baker DJ, Jones SW. The role of adipokines in skeletal muscle inflammation and insulin sensitivity. *J Inflamm (Lond)* 2018; 15: 9.
 200. Ralston JC, Lyons CL, Kennedy EB, Kirwan AM, Roche HM. Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues. *Ann Rev Nutr* 2017; 37: 77-102.
 201. Boden G. Obesity and free fatty acids. *Endocrinol Metab Clin North Am* 2008; 37: 635-ix.
 202. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. *Curr Diab Rep* 2006; 6: 177-81.
 203. Fink LN, Costford SR, Lee YS, et al. Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans. *Obesity (Silver Spring)* 2014; 22: 747-57.
 204. Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. *J Clin Invest* 2017; 127: 43-54.
 205. Capel F, Acquaviva C, Pitois E, et al. DHA at nutritional doses restores insulin sensitivity in skeletal muscle by preventing lipotoxicity and inflammation. *J Nutr Biochem* 2015; 26: 949-59.
 206. Freitas-Lopes MA, Mafra K, David BA, Carvalho-Gontijo R, Menezes GB. Differential location and distribution of hepatic immune cells. *Cells* 2017; 6: E48.
 207. Bibbo S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G. Gut microbiota as a driver of inflam-

- mation in nonalcoholic fatty liver disease. *Mediators Inflamm* 2018; 2018: 9321643.
208. Divella R, Mazzocca A, Daniele A, Sabba C, Paradiso A. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. *Int J Biol Sci* 2019; 15: 610-6.
209. Filip R, Radzki RP, Bienko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. *Clin Interv Aging* 2018; 13: 1879-91.
210. Zhang Q, Lou Y, Bai XL, Liang TB. Immunometabolism: a novel perspective of liver cancer microenvironment and its influence on tumor progression. *World J Gastroenterol* 2018; 24: 3500-12.
211. Morinaga H, Mayoral R, Heinrichsdorff J, et al. Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. *Diabetes* 2015; 64: 1120-30.
212. Van Furth R. Monocyte origin of Kupffer cells. *Blood Cells* 1980; 6: 87-92.
213. Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Buschenfelde KH, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. *J Hepatol* 1995; 22: 226-9.
214. Mayoral Monibas R, Johnson AMF, Osborn O, Traves PG, Mahata SK. Distinct hepatic macrophage populations in lean and obese mice. *Front Endocrinol* 2016; 7: 152.
215. Tencerova M, Aouadi M, Vangala P, et al. Activated Kupffer cells inhibit insulin sensitivity in obese mice. *FASEB J* 2015; 29: 2959-69.
216. Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-gamma activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. *Sci Rep* 2017; 7: 44612.
217. Cha JY, Kim DH, Chun KH. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Lab Anim Res* 2018; 34: 133-9.
218. Kamari Y, Shaish A, Vax E, et al. Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. *J Hepatol* 2011; 55: 1086-94.
219. Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. *Cell Mol Immunol* 2016; 13: 316-27.
220. Gonzalez-Dominguez E, Samaniego R, Flores-Sevilla JL, et al. CD163L1 and CLEC5A discriminate subsets of human resident and inflammatory macrophages in vivo. *J Leukoc Biol* 2015; 98: 453-66.
221. Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J. New aspects of lipotoxicity in nonalcoholic steatohepatitis. *Int J Mol Sci* 2018; 19.
222. Gao J, Xiao H, Li J, Guo X, Cai W, Li D. N-3 polyunsaturated fatty acids decrease long-term diabetic risk of offspring of gestational diabetes rats by postponing shortening of hepatic telomeres and modulating liver metabolism. *Nutrients* 2019; 11: 1699.
223. Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. *Pharmacol Ther* 2018; 181: 108-25.
224. Lalia AZ, Lanza IR. Insulin-sensitizing effects of omega-3 fatty acids: lost in translation? *Nutrients* 2016; 8: 329.
225. Huang W, Metlakunta A, Dedousis N, et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. *Diabetes* 2010; 59: 347-57.
226. Chang CC, Wu CL, Su WW, et al. Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. *Sci Rep* 2015; 5: 10096.
227. Paquissi FC. Immune imbalances in non-alcoholic fatty liver disease: from general biomarkers and neutrophils to interleukin-17 axis activation and new therapeutic targets. *Front Immunol* 2016; 7: 490.
228. Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. *Nature* 2016; 531: 253-7.
229. Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. *Cancer Cell* 2014; 26: 549-64.
230. Ghazarian M, Revelo XS, Nohr MK, et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. *Sci Immunol* 2017; 2.
231. Sheng L, Jiang B, Rui L. Intracellular lipid content is a key intrinsic determinant for hepatocyte viability and metabolic and inflammatory states in mice. *Am J Physiol Endocrinol Metab* 2013; 305: E1115-23.
232. Lebeaupin C, Proics E, de Bievillie CH, et al. ER stress induces NLRP3 inflammasome activation and hepatocyte death. *Cell Death Dis* 2015; 6: e1879.
233. Vasiljevic A, Bursac B, Djordjevic A, et al. Hepatic inflammation induced by high-fructose diet is associated with altered 11betaHSD1 expression in the liver of Wistar rats. *Eur J Nutr* 2014; 53: 1393-402.
234. Morgantini C, Jager J, Li X, et al. Liver macrophages regulate systemic metabolism through non-inflammatory factors. *Nat Metab* 2019; 1: 445-459.
235. Pandol SJ. *The Exocrine Pancreas*. San Rafael, 2010.
236. Nussey S, Whitehead S. *Endocrinology: An Integrated Approach*. Oxford, 2001.
237. Ionescu-Tirgoviste C, Gagnic PA, Gubceac E, et al. A 3D map of the islet routes throughout the healthy human pancreas. *Sci Rep* 2015; 5: 14634.
238. Da Silva Xavier G. The cells of the islets of Langerhans. *J Clin Med* 2018; 7.
239. Torres N, Noriega L, Tovar AR. Nutrient modulation of insulin secretion. *Vitam Horm* 2009; 80: 217-44.
240. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. *J Clin Invest* 2011; 121: 2118-25.
241. Wortham M, Sander M. Mechanisms of beta-cell functional adaptation to changes in workload. *Diabetes Obes Metab* 2016; 18 Suppl 1: 78-86.
242. Cerf ME. Beta cell dysfunction and insulin resistance. *Front Endocrinol (Lausanne)* 2013; 4: 37.
243. Lightfoot YL, Chen J, Mathews CE. Oxidative stress and beta cell dysfunction. *Methods Mol Biol* 2012; 900: 347-62.
244. Eizirik DL, Miani M, Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. *Diabetologia* 2013; 56: 234-41.
245. Lu H, Koshkin V, Allister EM, Gyulkhandanyan AV, Wheeler MB. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. *Diabetes* 2010; 59: 448-59.
246. Robertson RP. Arachidonic acid metabolite regulation of insulin secretion. *Diabetes Metab Rev* 1986; 2: 261-96.
247. Robertson RP. Eicosanoids as pluripotential modulators of pancreatic islet function. *Diabetes* 1988; 37: 367-70.
248. Tran PQ, Gleason CE, Poitout V, Robertson RP. Prostaglandin E(2) mediates inhibition of insulin secretion by interleukin-1beta. *J Biol Chem* 1999; 274: 31245-8.

249. Gurgul-Convey E, Hanzelka K, Lenzen S. Mechanism of prostacyclin-induced potentiation of glucose-induced insulin secretion. *Endocrinology* 2012; 153: 2612-22.
250. Lytrivi M, Igoillo-Esteve M, Cnop M. Inflammatory stress in islet beta-cells: therapeutic implications for type 2 diabetes? *Curr Opin Pharmacol* 2018; 43: 40-5.
251. Morris DL. Minireview: emerging concepts in islet macrophage biology in type 2 diabetes. *Mol Endocrinol* 2015; 29: 946-62.
252. Yong J, Itkin-Ansari P, Kaufman RJ. When less is better: ER stress and beta cell proliferation. *Dev Cell* 2016; 36: 4-6.
253. Jurgens CA, Toukatly MN, Fligner CL, et al. Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. *Am J Pathol* 2011; 178: 2632-40.
254. Westwell-Roper CY, Chehroudi CA, Denroche HC, Courtade JA, Ehses JA, Verchere CB. IL-1 mediates amyloid-associated islet dysfunction and inflammation in human islet amyloid polypeptide transgenic mice. *Diabetologia* 2015; 58: 575-85.
255. Youm YH, Adijiang A, Vandamagsar B, Burk D, Ravussin A, Dixit VD. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. *Endocrinology* 2011; 152: 4039-45.
256. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. *J Clin Invest* 2002; 110: 851-60.
257. Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. *Nat Rev Immunol* 2019; 19: 734-46.
258. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes* 2005; 54 Suppl 2: S97-107.
259. Gurgul-Convey E, Kaminski MT, Lenzen S. Physiological characterization of the human EndoC-betaH1 beta-cell line. *Biochem Biophys Res Commun* 2015; 464: 13-9.
260. Gurgul-Convey E, Mehmeti I, Plotz T, Jorns A, Lenzen S. Sensitivity profile of the human EndoC-betaH1 beta cell line to proinflammatory cytokines. *Diabetologia* 2016; 59: 2125-33.
261. Everett BM, Donath MY, Pradhan AD, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. *J Am Coll Cardiol* 2018; 71: 2392-401.
262. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. *Curr Opin Endocrinol Diabetes Obes* 2010; 17: 314-21.
263. Kataria Y, Ellervik C, Mandrup-Poulsen T. Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. *Semin Immunopathol* 2019; 41: 413-25.
264. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. *Diabetes* 2007; 56: 2356-70.
265. Chan JY, Lee K, Maxwell EL, Liang C, Laybutt DR. Macrophage alterations in islets of obese mice linked to beta cell disruption in diabetes. *Diabetologia* 2019; 62: 993-9.
266. Kamata K, Mizukami H, Inaba W, et al. Islet amyloid with macrophage migration correlates with augmented beta-cell deficits in type 2 diabetic patients. *Amyloid* 2014; 21: 191-201.
267. Eguchi K, Nagai R. Islet inflammation in type 2 diabetes and physiology. *J Clin Invest* 2017; 127: 14-23.
268. Eguchi K, Manabe I, Oishi-Tanaka Y, et al. Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. *Cell Metab* 2012; 15: 518-33.
269. Zinselmeyer BH, Vomund AN, Saunders BT, Johnson MW, Carrero JA, Unanue ER. The resident macrophages in murine pancreatic islets are constantly probing their local environment, capturing beta cell granules and blood particles. *Diabetologia* 2018; 61: 1374-1383.
270. Ying W, Lee YS, Dong Y, et al. Expansion of islet-resident macrophages leads to inflammation affecting beta cell proliferation and function in obesity. *Cell Metab* 2019; 29: 457-474.e5.
271. Gurgul-Convey E, Lenzen S. Protection against cytokine toxicity through endoplasmic reticulum and mitochondrial stress prevention by prostacyclin synthase overexpression in insulin-producing cells. *J Biol Chem* 2010; 285: 11121-8.
272. Robertson RP, Chen M, McRae JR, Metz SA. Improvement of insulin secretion in diabetics by a prostaglandin synthesis inhibitor. *Adv Exp Med Biol* 1979; 119: 227-31.
273. Sato N, Kaneko M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. *Diabetes* 2010; 59: 1092-100.
274. Barden AE, Mas E, Croft KD, Phillips M, Mori TA. Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin. *Am J Clin Nutr* 2015; 102: 1357-64.
275. Neuhofer A, Zeyda M, Mascher D, et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. *Diabetes* 2013; 62: 1945-56.
276. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. *FASEB J* 2011; 25: 2399-407.
277. Titos E, Rius B, Gonzalez-Periz A, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. *J Immunol* 2011; 187: 5408-18.
278. Zhou W, Sailani MR, Contrepois K, et al. Longitudinal multi-omics of host-microbe dynamics in prediabetes. *Nature* 2019; 569: 663-71.